VIDA

VIDA modernizes lung and respiratory care, empowering healthcare organizations and physicians to improve patient outcomes, streamline care coordination and drive efficiencies through a comprehensive approach, proven quality, and clinical leadership. Through quantitative data intelligence and impactful visualizations, VIDA helps physicians manage patients with or at risk of chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), lung cancer, and now, COVID-19. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed and TGA registered for clinical use in the US, European Economic Area, Canada, and Australia. Learn more at vidalung.ai.

VIDA headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Health Care, Medical, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $6.4B in funding across 192 round(s). With a team of 51-100 employees, VIDA is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - VIDA, raised $300.0K. Discover more about their projects, partnerships, and impact on our platform.